Ultime notizie per Nano Dimension (NASDAQ:NNDM) Azioni

Nano Dimension

Nano Dimension Ltd provide industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research and academia, along with government organizations.

Nano Dimension Ltd. - American Depositary Shares

Nano Dimension Ltd

<a href="https://www.reuters.com/business/aerospace-defense/qatar-shuts-down-airspace-temporarily-amid-regional-crisis-2025-06-23/">https://www.reuters.com/business/aerospace-defense/qatar-shuts-down-airspace-temporarily-amid-regional-crisis-2025-06-23/</a>

Macro Economic Events

News

Politics

Economics

General

iShares MSCI Israel Capped Investable Market Index Fund

'Qatar Shuts Down Airspace Temporarily Amid Regional Crisis'- Reuters

Truist Securities analyst Asthika Goonewardene reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $43 to $55.

Price Target

Reiteration

Analyst Ratings

EXEL

Truist Securities Reiterates Buy on Exelixis, Raises Price Target to $55

<a href="https://www.bloomberg.com/news/features/2025-06-23/satellite-images-suggest-us-avoided-iran-s-reactors">https://www.bloomberg.com/news/features/2025-06-23/satellite-images-suggest-us-avoided-iran-s-reactors</a>

'Satellite Images Suggest US Avoided Iran's Nuclear Reactors'- Bloomberg

Citigroup analyst Jon Tower maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $245 to $253.

Citigroup Maintains Buy on Darden Restaurants, Raises Price Target to $253

<a href="https://www.bloomberg.com/news/articles/2025-06-23/us-uk-urge-citizens-in-qatar-to-shelter-as-iran-weighs-response">https://www.bloomberg.com/news/articles/2025-06-23/us-uk-urge-citizens-in-qatar-to-shelter-as-iran-weighs-response</a>

'US, UK Urge Citizens in Qatar to Shelter in Place as Iran Weighs Response'- Bloomberg

Compass Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">treatment-resistant depression (TRD)</a>.
Despite meeting the primary endpoint, the company&#8217;s stock experienced a significant decline. This was largely attributed to investor and analyst expectations for a more pronounced clinical effect.
The ongoing COMP005 trial is a randomized, double-blind, placebo-controlled study, which has dosed 258 participants and aims to assess the efficacy and safety of a single dose of 25 mg COMP360 versus placebo for reducing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46048057/compass-pathways-successfully-achieves-primary-endpoint-in-first-phase-3-trial-evaluating-comp360-" rel="noreferrer noopener">symptom severity in TRD</a>.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/02/44024383/psychedelics-focused-compass-pathways-has-established-itself-as-credible-cns-biotechnology-company-analyst-says" target="_blank" rel="noreferrer noopener">Psychedelics-Focused Compass Pathways Has Established Itself As &#8216;Credible CNS Biotechnology Company,&#8217; Analyst Says</a>
The trial comprises three parts: Part A, which has recently concluded and was blinded through 6 weeks; Part B, which remains blinded through week 26; and Part C, which contains an open-label treatment part from week 26 to 52.
The trial met its primary endpoint, the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6.
A single dose of COMP360 25 mg versus placebo demonstrated a statistically significant reduction in symptom severity with a p-value of &lt;0.001 and a clinically meaningful difference of -3.6 in change at the primary endpoint.
The company plans to discuss these preliminary COMP005 data with the U.S. Food and Drug Administration (FDA), which has not yet reviewed the data.
The second ongoing pivotal Phase 3 COMP006 trial continues to enroll well, with 26-week data expected in the second half of 2026.
<h2 class="wp-block-heading">Key COMP005 Findings</h2>
Efficacy Data (MADRS): Single dose of COMP360 25 mg versus placebo with a mean treatment difference of -3.6 points.
Reuters noted that while Compass said the results were &#8220;statistically significant,&#8221; some analysts and investors were disappointed, as they had hoped for a five-point drop in symptoms, sending the stock down almost 47%.
Based on the latest data review for the 005 and 006 studies, safety findings are consistent with previous studies of COMP360, and there are no new or unexpected safety findings. Neither study has evidence of a clinically meaningful imbalance between treatment arms in suicidality.
Price Action: CMPS stock is trading lower by 47.3% to $2.44 at last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/01/43105398/fda-approves-johnson-johnsons-treatment-as-first-monotherapy-for-treatment-resistant-depression" target="_blank" rel="noreferrer noopener">FDA Approves Johnson &amp; Johnson&#8217;s Treatment As First Monotherapy For Treatment-Resistant Depression</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

CMPS

Why Is Compass Pathways Stock Trading Lower On Monday?

WIIM

WOLF

Wolfspeed shares are trading lower after following a report suggesting thar the company plans on filing for bankruptcy by July 1. On Sunday, the company announced it entered into a  Restructuring Support Agreement.

At 69, many Americans are thinking about slowing down, if they haven't already — but not everyone. One Reddit user recently <a href="https://www.reddit.com/r/SocialSecurity/comments/1lcaxsd/my_husband/">shared</a> that her husband, born in January 1956, is still working full time and loves his job. He's also the only one at his hospital who performs certain specialized tests, so his employer is eager to keep him. While he's already enrolled in Medicare, he hasn't yet started collecting Social Security retirement benefits.&nbsp;
So, their question is: should he claim now or keep waiting?
Let's look at how Social Security works in this scenario.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
<h2 class="wp-block-heading">Full Retirement Age Means No Earnings Limit</h2>
First, it's important to know that once someone reaches their full retirement age, there's no limit on how much they can earn while receiving Social Security benefits, per <a href="https://www.ssa.gov/benefits/retirement/planner/whileworking.html">Social Security Administration rules</a>.
For someone born in January 1956, full retirement age is 66 years and 4 months. That means this man reached FRA back in May 2022. Since then, he's been eligible to collect his full retirement benefit with no penalty for working full-time.
In other words, yes — he can collect Social Security now and keep working as much as he wants. There's no reduction in benefits due to his job income, and he'll still be contributing to Social Security through payroll taxes.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
<h2 class="wp-block-heading">What Happens If He Waits Until 70?</h2>
If he chooses not to claim just yet, his benefit amount will continue to grow. <a href="https://www.benzinga.com/personal-finance/management/25/06/45987399/35-year-old-woman-shocked-by-5000-social-security-overpayment-notice-says-she-never-received-benefits">Social Security</a> increases your benefit by about 8% each year you delay claiming after your full retirement age, up until age 70.
Because he's now 69, he's less than a year away from maxing out that delayed retirement credit. If he waits until he turns 70, his monthly benefit could be roughly 24% higher than it would have been at his FRA.
That increase lasts for the rest of his life — and could also benefit a <a href="https://www.benzinga.com/personal-finance/25/04/44717804/suze-orman-says-too-many-people-think-their-spouse-will-need-just-50-of-their-household-income-when-they-die-heres-why-theyre-wrong">surviving spouse</a> if she later receives spousal or survivor benefits.
<h2 class="wp-block-heading">Can Working Increase Future Payments?</h2>
Yes. Even if he starts collecting Social Security now, his benefit might still increase over time. That's because the Social Security Administration continues to review earnings records. If his recent work years are among his 35 highest-earning years, the agency could recalculate his benefit upward.
He'll receive a notice if his payment increases due to these new earnings.
See Also: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a>
<h2 class="wp-block-heading">What's the Right Move?</h2>
There's no one-size-fits-all answer. If the couple wants to lock in the higher monthly benefit, they might wait until he turns 70. On the other hand, if they'd like to start receiving money now — and he's already past his full retirement age — there's no financial penalty for doing so. He can collect benefits while continuing his career.
Factors to consider include their overall financial situation, life expectancy, how long he plans to work, and whether the added income would help meet their current goals.
<h2 class="wp-block-heading">Bottom Line</h2>
At 69 and past his full retirement age, this worker has options. He can safely claim his Social Security benefits now without reducing his payments — even if he continues to earn a full-time income. But if he waits just a little longer, he'll lock in a bigger monthly check for life. Either path can work; it all depends on what fits their needs best.
Before making a decision, it may help to speak with a <a href="https://www.benzinga.com/money/best-online-financial-advisors">financial advisor</a> or use Social Security's <a href="https://www.ssa.gov/OACT/COLA/RTeffect.html">online tools</a> to estimate benefits.
Read Next: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
Image: Shutterstock

Personal Finance

Still Working At 69, Eligible For Social Security: Should He Keep Waiting Or Claim Now?

Yum Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) has outperformed the market over the past 20 years by 2.2% on an annualized basis producing an average annual return of 10.58%. Currently, Yum Brands has a market capitalization of $38.86 billion. 
Buying $100 In YUM: If an investor had bought $100 of YUM stock 20 years ago, it would be worth $749.52 today based on a price of $139.81 for YUM at the time of writing.
<h3>Yum Brands's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750693516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Yum Brands Stock In The Last 20 Years

Citigroup analyst Keith Horowitz maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and raises the price target from $195 to $200.

Citigroup Maintains Neutral on M&T Bank, Raises Price Target to $200

AST SpaceMobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) gets downgraded, Voyager Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) stock continues its post-IPO slide and Rocket Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) prepares another Electron launch for Tuesday.&nbsp;
Here's a look at recent highlights, news catalysts and upcoming events in the <a href="https://www.benzinga.com/news/space/25/06/45954798/voyagers-ipo-ast-spacemobile-climbs-weekly-space-stock-countdown">space stock sector.&nbsp;</a>
ASTS: AST SpaceMobile shares hit the brakes on Monday after Scotiabank analyst Andres Coello downgraded the stock from Sector Outperform to Sector Perform with a $45.40 <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings">price target.&nbsp;</a>
Read Next: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46030182/circle-stock-rockets-540-cathie-wood-says-weve-just-begun?utm_source=articleShare">Circle Stock Rockets 540%: Cathie Wood Says &#8216;We&#8217;ve Just Begun&#8217;</a>
ASTS stock <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46033050/ast-spacemobile-asts-surges-29-this-week-ahead-of-russell-1000-inclusion-and-major-deals">has risen more than </a>90% over the past month, and the satellite-to-smartphone communications company is set to join the Russell 1000 Index on June 27.
RKLB: Last week, Rocket Lab announced two new Electron missions for a "confidential commercial customer" with the first scheduled to launch on Tuesday.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Our next launch attempt for the &#39;Symphony In The Stars&#39; mission is now scheduled for Tuesday, June 24th. Launch window opens: &#x1f680;NZT &#x7C; 7:00 PM &#x1f680;07:00 UTC &#x1f680;EDT &#x7C; 03:00 AM &#x1f680;PDT &#x7C; 12:00 AM Mission info: <a href="https://t.co/UO2lz4k9Jk">https://t.co/UO2lz4k9Jk</a> <a href="https://t.co/iQuLsoTPVg">pic.twitter.com/iQuLsoTPVg</a>
&mdash; Rocket Lab (@RocketLab) <a href="https://twitter.com/RocketLab/status/1936886534734766191?ref_src=twsrc%5Etfw">June 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rocket Lab stock has risen more than 23% over the past five days, and the rally continues on Monday. 
VOYG: shares have fallen 20% since its IPO earlier in June. The stock began trading on June 11 at $69.75 per share and was trading at $44.73 on Monday.&nbsp;
LMT: Shares of Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) are trending and trading higher as geopolitical tensions increased following the U.S. attacks on Iranian targets.&nbsp;
Last week, Lockheed's Chief Operating Officer Frank St John <a href="https://www.ft.com/content/cc762511-18b9-4d29-985d-0116751ef59c">told</a> the Financial Times that the company presented a proposal for an air-defense system to British government officials.&nbsp;
The <a href="https://www.benzinga.com/markets/large-cap/25/06/46033252/lockheed-martin-eyes-uk-missile-shield-role-amid-rising-global-tensions">project would deploy</a> space‑based sensors and interceptors and align with President Donald Trump's Golden Dome initiative in the United States.&nbsp;
Read Next:<a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare">&nbsp;</a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45971345/sunrun-first-solar-plunge-solar-stocks-hit-hard-by-trump-tax-bill-latest?utm_source=articleShare">Sunrun, First Solar Plunge—Solar Stocks Hit Hard By Trump Tax Bill: Latest</a>&nbsp;</li>
</ul>
Image: Shutterstock&nbsp;

SPACE

IPOs

Tech

ASTS

RKLB

VOYG

AST SpaceMobile Stock Downgraded, Rocket Lab Prepares Electron Launch: Space Stock Countdown

Maxim Group analyst Tate Sullivan maintains Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) with a Buy and raises the price target from $57 to $62.

ESEA

Maxim Group Maintains Buy on Euroseas, Raises Price Target to $62

Truist Securities analyst Jamie Cook maintains Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) with a Buy and raises the price target from $396 to $414.

Truist Securities Maintains Buy on Caterpillar, Raises Price Target to $414

Truist Securities analyst Scot Ciccarelli maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Hold and raises the price target from $72 to $74.

Truist Securities Maintains Hold on CarMax, Raises Price Target to $74

Maxim Group analyst Tate Sullivan maintains Globus Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBS#NASDAQ">GLBS</a>) with a Buy and lowers the price target from $4 to $3.

GLBS

Maxim Group Maintains Buy on Globus Maritime, Lowers Price Target to $3

Truist Securities analyst Miller Jump downgrades Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) from Buy to Hold and raises the price target from $21 to $24.5.

Downgrades

BASE

Truist Securities Downgrades Couchbase to Hold, Raises Price Target to $24.5

Lake Street analyst Mark Smith maintains Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) with a Buy and lowers the price target from $12.5 to $11.

SWBI

Lake Street Maintains Buy on Smith & Wesson Brands, Lowers Price Target to $11

-&nbsp; ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi&#xAE; (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination
-&nbsp; ATNM-400 is more efficacious than both Pluvicto&#xAE; (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted radiotherapy in prostate cancer in vitro and in vivo models and overcome resistance in prostate cancer tumors that failed Pluvicto&#xAE; therapy
-&nbsp; ATNM-400's target is highly differentiated from PSMA as it is implicated in disease biology, contributing to disease progression, faster progression to castration resistance and poorer survival outcomes with target expression reported following androgen receptor inhibitor and PSMA radiotherapy
-&nbsp; Data further supports ATNM-400's potential to address critical gaps in prostate cancer treatment as a monotherapy or in sequence with other therapeutic modalities
NEW YORK, June 23, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today reported new preclinical data from its first-in-class, non-PSMA targeting radiotherapy prostate cancer candidate ATNM-400, that leverages the potent alpha-particle emitter Actinium-225 (Ac-225) isotope, at the Society of Nuclear Medicine &amp; Molecular Imaging (SNMMI) annual meeting being held June 21st – 24th, 2025, in New Orleans, Louisiana. The data presented at SNMMI showed ATNM-400 has superior potency compared Xtandi&#xAE;&nbsp;(enzalutamide) and is highly efficacious in Xtandi&#xAE;&nbsp;resistant prostate models. Xtandi is an androgen receptor inhibitor (ARPI) therapy developed and marketed by Astellas and Pfizer that is approved for three stages of prostate cancer and generated sales of $5.9 billion in 2024. Actinium also presented additional new data showing ATNM-400 is more efficacious than PSMA-617 labeled with both Lutetium-177 (Lu-177) and Ac-225 and that ATNM-400 also overcomes resistance to Pluvicto&#xAE;&nbsp;(Lu-177-PSMA-617). Pluvicto&#xAE;&nbsp;is developed and marketed by Novartis and generated sales of $1.4 billion in 2024. ATNM-400 represents a transformational therapeutic candidate being developed to overcome limitations of current prostate cancer therapies such as Xtandi&#xAE;&nbsp;and Pluvicto&#xAE;&nbsp;and improve outcomes over what is currently achievable.

ATNM

Actinium Pharma Reports New Preclinical Data From Non-PSMA Targeting Radiotherapy Prostate Cancer Candidate ATNM-400, At SNMMI Annual Meeting

Fiserv Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FI#NASDAQ">FI</a>) and PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46049194/fiserv-and-paypal-expand-partnership-to-advance-stablecoin-payments" rel="noreferrer noopener">new partnership</a> Monday focused on creating interoperability between their stablecoins, FIUSD and PayPal USD (PYUSD), to streamline global digital payments.
The initiative will target use cases like international transactions, merchant payments, and faster settlements, aiming to integrate programmable stablecoins into traditional financial systems. 
By combining their global reach and technical platforms, the two firms hope to drive broader adoption of blockchain-powered financial tools.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46034000/circles-flagship-stablecoin-usdc-set-for-rapid-growth-analyst-says-regulatory-climate-key" target="_blank" rel="noreferrer noopener">Circle&#8217;s Flagship Stablecoin USDC Set For Rapid Growth, Analyst Says Regulatory Climate Key</a>     
Fiserv COO Takis Georgakopoulos said the partnership reinforces the company&#8217;s goal of expanding stablecoin-based payments across banking and commerce. 
PayPal EVP Frank Keller noted the collaboration could help resolve common financial challenges such as slow settlement times and currency fluctuations.
As part of the effort, Fiserv is developing FIUSD to support next-gen banking solutions for financial institutions. PYUSD, launched in 2023, has already been applied to remittances, startup funding, and invoice processing.
Beyond the PayPal partnership, Fiserv is also expanding its stablecoin initiatives through a separate collaboration.
Circle Internet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) and Fiserv announced a <a href="https://www.benzinga.com/pressreleases/25/06/b46049537/circle-and-fiserv-announce-strategic-collaboration-to-power-stablecoin-payments-across-financial-e" target="_blank" rel="noreferrer noopener">partnership</a> to enhance digital dollar payments using stablecoin technology.
The collaboration will integrate Circle&#8217;s USDC platform with Fiserv&#8217;s financial services tools to enable faster, lower-cost domestic and international transactions.
The goal is to offer banks and fintechs real-time settlements and cross-border capabilities within a secure, compliant framework.
Circle CEO Jeremy Allaire said the partnership reflects a shared commitment to expanding stablecoin-based financial tools.
Rollout will happen in stages and depend on regulatory approval and partner readiness.
Separately, Fiserv announced plans to launch a new stablecoin, FIUSD, by year-end and integrate it into its global payments infrastructure. Built with Paxos and Circle, FIUSD will offer banks and merchants seamless access to digital assets via blockchain platforms like Solana, enabling faster, cost-effective transactions across Fiserv&#8217;s vast financial network.
Investors following this development may also want to track activity around Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) and Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), along with related ETFs such as Amplify Transformational Data Sharing ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLOK#NYSE">BLOK</a>) and Bitwise Crypto Industry Innovators ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITQ#NYSE">BITQ</a>).
Price Action: FI shares are trading higher by 3.92% at $169.78, PYPL was up 2.30% at $71.66, and CRCL rose 8.81% to $262 at last check Monday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46050890/bitcoin-ethereum-xrp-dogecoin-weaken-on-iran-israel-tensions-reclaim-105000-or-brace-for-sideways-summer" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Weaken On Iran-Israel Tensions – Reclaim $105,000 Or Brace For Sideways Summer</a></li>
</ul>
Photo via Shutterstock

BITQ

BLOK

COIN

CRCL

PYPL

Fiserv, PayPal Expand Partnership To Advance Stablecoin Payments

Lake Street analyst Mark Smith maintains Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) with a Buy and lowers the price target from $3 to $2.

Comments

Nano Dimension

Notizie

Ultime notizie per Nano Dimension (NASDAQ:NNDM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO